About METRO INTERNATIONAL BIOTECH, LLC
MetroBiotech, LLC is a clinical-stage biotechnology company developing first-in-class therapeutics targeting NAD+ biology to enhance human healthspan and treat age-related diseases. The company focuses on restoring and sustaining NAD+ levels through proprietary compounds like MIB-626 and MIB-725.
Development of NAD+ precursor therapeuticsClinical trials for age-related diseases (e.g., Alzheimer’s, chronic kidney disease, muscle strength and endurance)Proprietary NAD+ imaging technology using in vivo MRS with a 7-tesla magnetPharmaceutical-grade manufacturing standards under FDA oversightChemistry-driven drug discovery approach with expertise in pharmacokinetics and pharmacodynamics
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to METRO INTERNATIONAL BIOTECH, LLC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.